Trial reportBMC medicine2025
Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological characterization of cervical squamous cell carcinoma withOncology letters · 2026Article
- Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundOur phase 2 study has shown the efficacy and safety of sintilimab plus anlotinib as second- or later-line therapy in patients with programmed death-ligand 1 (PD-L1)-positive recurrent or metastatic cervical cancer who had failed prior chemotherapy. Here, we presented updated survival outcomes after a 3-year follow-up.
methodsPatients received a regimen comprising 200 mg of sintilimab administered once on day 1 and 10 mg of anlotinib once daily on days 1-14 every 3 weeks. Treatment was continued until disease progression or intolerable toxicity. Updated overall survival (OS) and duration of response (DoR) were reported. For patients who received subsequent treatment after progression on sintilimab plus anlotinib, the second progression-free survival (PFS2) and objective response rate on subsequent treatment (ORR2) were analyzed.
resultsBetween December 2019 and December 2020, a total of 42 patients were enrolled. As of July 12, 2024, the median follow-up duration was 47.2 months (range, 0.6-52.9). Median OS was 17.8 months (95% confidence interval [CI], 12.3-36.5) for 42 patients, and the median DoR was 13.2 months (95% CI, 8.2-41.8) for 23 patients with objective response. Median PFS2 was 23.6 months (95% CI, 12.5-29.8) and the ORR2 was 46.1% in 13 patients. Multivariate analysis identified PIK3CA mutation (hazard ratio = 3.43; 95% CI, 1.04-11.30; P = 0.043) as an independent prognostic factor for OS. The incidence of grade ≥ 3 treatment-related adverse events did not increase with extended follow-up.
conclusionsLong-term follow-up showed persistent antitumor activity and maintained safety of sintilimab plus anlotinib in pre-treated patients with PD-L1-positive advanced cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.